Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price objective on MorphoSys AG (ETR:MOR) in a research note published on Monday, July 24th. The firm currently has a neutral rating on the stock.
Other research analysts also recently issued reports about the stock. Independent Research GmbH set a €77.00 ($90.59) price target on shares of MorphoSys AG and gave the stock a buy rating in a research note on Monday, July 17th. Berenberg Bank set a €68.00 ($80.00) price target on shares of MorphoSys AG and gave the stock a buy rating in a research note on Friday, July 14th. HSBC Holdings plc set a €59.00 ($69.41) price target on shares of MorphoSys AG and gave the stock a neutral rating in a research note on Friday, July 14th. Commerzbank Ag set a €76.00 ($89.41) price target on shares of MorphoSys AG and gave the stock a buy rating in a research note on Tuesday, June 6th. Finally, J P Morgan Chase & Co reissued a neutral rating on shares of MorphoSys AG in a research note on Monday, July 17th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of €69.57 ($81.85).
MorphoSys AG (MOR) traded down 0.694% during midday trading on Monday, reaching €56.922. 853 shares of the company’s stock were exchanged. MorphoSys AG has a 12 month low of €35.72 and a 12 month high of €70.90. The stock’s market cap is €1.65 billion. The firm has a 50 day moving average of €61.24 and a 200-day moving average of €57.85.
WARNING: This story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/08/19/morphosys-ag-mor-given-a-55-00-price-target-at-goldman-sachs-group-inc-the-updated-updated-updated.html.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
What are top analysts saying about MorphoSys AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MorphoSys AG and related companies.